<DOC>
	<DOCNO>NCT01905943</DOCNO>
	<brief_summary>This multicenter , open-label , single-arm study evaluate safety efficacy obinutuzumab alone combination chemotherapy participant previously untreated relapsed/refractory chronic lymphocytic leukemia ( CLL ) . Participants receive 6 cycle single-agent obinutuzumab obinutuzumab combination chemotherapy investigator 's discretion . Each participant follow 30 month last participant enrol . Total length study anticipate approximately 5 year .</brief_summary>
	<brief_title>A Safety And Efficacy Study Obinutuzumab Alone Combination With Chemotherapy Participant With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>Previously untreated document CLL accord national cancer institute/international workshop CLL ( NCI/iwCLL ) criterion OR relapse and/or refractory document CLL participant require treatment accord NCI/iwCLL criterion ; participant 3 relapse eligible Refractory participant last treatment singleagent therapy , singleagent chemotherapy , singleagent antibody Participants 17pdeletion and/or p53 mutation may include investigator 's discretion Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy great ( &gt; ) 6 month accord investigator 's opinion Adequate hematological function Participants receive 3 previous CLL treatment line Documented transformation CLL aggressive lymphoma ( Richter 's transformation ) Participants refractory immunochemotherapy Participants abnormal laboratory value One individual organ/system impairment score 4 assessed cumulative illness rating scale ( CIRS ) definition , exclude eye , ear , nose , throat larynx organ system Participants history progressive multifocal leukoencephalopathy ( PML ) History severe allergic anaphylactic reaction monoclonal antibody therapy Known hypersensitivity study drug History prior malignancy unless malignancy treat curative intent remission without treatment great equal ( &gt; /= ) 5 year prior enrollment exception curativelytreated basal cell carcinoma , squamous cell carcinoma skin , low grade situ carcinoma cervix , low grade , early stage localize prostate cancer treat surgically curative intent Regular treatment corticosteroid 28 day prior start Cycle 1 , Day 1 , unless administer indication CLL dose equivalent less equal ( &lt; /= ) 30 milligram per day ( mg/day ) prednisone Regular treatment immunosuppressive medication follow previous organ transplantation Evidence significant , uncontrolled concomitant disease Known active bacterial , viral , fungal , mycobacterial , parasitic , infection ( exclude fungal infection nail bed ) major episode infection require treatment intravenous ( IV ) antibiotic hospitalization within 28 day prior start Cycle 1 , Day 1 Vaccination live vaccine within 28 day prior start Cycle 1 , Day 1 Major surgery ( within 28 day prior start Cycle 1 , Day 1 ) , diagnosis Positive chronic hepatitis B , hepatitis C , human Tlymphotropic virus 1 ( HTLV 1 ) human immunodeficiency virus ( HIV ) infection Pregnant lactate woman Fertile men woman childbearing potential Participation another clinical trial drug intervention within 28 day prior start Cycle 1 , Day 1 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>